



Drug Name: Kalydeco (ivacaftor)
Date: 8/2018

Drug Name:	Kalydeco (ivacaftor)
Required Medical Information:	<ul style="list-style-type: none"> • Patient is 2 years of age or older • Member has a diagnosis of Cystic Fibrosis • Genetic testing performed to detect a mutation in the cystic fibrosis transmembrane conductance regulatory (CFTR) gene. • Test positive for ANY of the following mutations? 1) A455E, 2) A1067T, 3) D110E, 4) D110H, 5) D579G, 6) D1152H, 7) D1270N, 8) E56K, 9) E193K, 10) E831X, 11) F1052V, 12) F1074L, 13) G178R, 14) G551D, 15) G551S, 16) G1069R, 17) G1244E, 18) G1349D, 19) K1060T, 20) L206W, 21) P67L, 22) R74W, 23) R117C, 24) R117H, 25) R347H, 26) R352Q, 27) R1070Q, 28) R1070W, 29) S549N, 30) S549R, 31) S945L, 32) S977F, 33) S1251N, 34) S1255P, 35) 711+3A→G, 36) 2789+5G→A, 37) 3272-26A→G, 38) 3849+10kbC→T • The patient homozygous for the F508del mutation in the CFTR gene • Kalydeco will NOT be used in combination with Orkambi (lumacaftor/ivacaftor) or Symdeko (tezacaftor/ivacaftor)
Coverage duration:	12 months